Indevus gains US patent for Sanctura XR
This article was originally published in Scrip
Executive Summary
Indevus Pharmaceuticalshas announced the issue of a US patent No 7,410,978, covering its once-daily product, Sanctura SR (trospium chloride extended-release tablets), a treatment for the symptoms of overactive bladder. The patent is licensed exclusively to Indevus by the patent's assignee, Supernus Pharmaceuticals. Last September, Indevus granted Allergan an exclusive sublicence to market the product in the US; Allergan and Indevus launched the product in the US in January. Allergan also has rights for the product in Canada (Scrip Online, June 6th, 2008).